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Imidazolium labelling permits the sensitive
mass-spectrometric detection of N-glycosides
directly from serum†
Yao-Yao Zhang,‡a Mattia Ghirardello, ‡b Ting Wang,a Ai-Min Lu,c Li Liu, a
Josef Voglmeir *a and M. Carmen Galan *b
A novel imidazolium derivative (GITag) shows superior ionisation
and consequently allows increased mass spectrometric detection
capabilities of oligosaccharides and N-glycans. Here we demon-
strate that human serum samples can be directly labelled by GITag
on a MALDI target plate, abrogating prevalently required sample
pretreatment or clean-up steps.
Subtle N-glycosylation changes of serum proteins such as
immunoglobulins, lipoproteins, or haptoglobin often indicate
the transition from a healthy to a pathological state of the
body.1–7 Alterations of serum N-glycosylation were described for
various types of cancers, autoimmune diseases, and other
diseases,8–12 which resulted in the identification of disease-
associated N-glycosylation signatures.13–15 The discovery of
glycan biomarkers and the subsequent detection of these
altered N-glycosylation patterns in clinical implementations
require the development of fast and sensitive automatable
mass spectrometric analysis methods, with access to a suffi-
cient amount of sample and the analyte limit of detection being
one of the main hurdles. In order to address these issues,
minimizing or completely avoiding sample enrichment, trans-
fer or centrifugation would be very beneficial in clinical appli-
cations (see ESI†). Electrospray ionisation mass spectrometry
(ESI-MS) and matrix-assisted laser desorption/ionisation mass
spectrometry (MALDI-ToF-MS) provide unique capabilities
regarding the sampling throughput and the required analysis
times.16–21 Currently, the mass spectrometric analysis of total
serum N-glycans requires (1) an enzymatic or chemical glycan
release step, (2) the reductive amination with functionalised
primary amine tags, and (3) a sample clean-up step for the
isolation of the derivatised N-glycan fraction by solid-phase
extraction before sample application and analysis.22–25 The
derivatisation of the reducing end of N-glycans with fluorescent
or hydrophobic amine tags allows the effective clean-up and/
or chromatographic separation and sensitive detection of
N-glycans in the low femtomol range.26–28 2-Aminobenzamide
(2AB) is arguably the most common fluorescent derivatisation
tag used in mass spectrometric N-glycan analysis and shows
similar ionisation efficiencies (within the same magnitude) for
ESI-MS and MALDI-ToF as other N-glycan derivatisation
agents such as 4-aminobenzoic acid 2-diethylaminoethyl
ester (procaine), 4-amino-N-[(2-diethylamino)ethyl]benzamide
(procainamide), 2-amino benzoic acid butyl ester (ABBE) and
2-amino benzoic acid ethyl ester (ABEE).29 As an attempt to
improve the ionisation efficiency of serum N-glycans, the
introduction of a permanent charge into the N-glycan derivati-
sation tag was proposed and several elegant attempts to modify
oligosaccharides using cationic hydrazides with quaternary
ammonia moieties were reported.30,31 However, a comparison
of the electrospray response of derivatised and native oligosac-
charides during mass spectrometric analysis showed only mar-
ginal increases in signal intensities in the range of one order of
magnitude,30,31 which could be attributed to the relatively low
derivatisation yields of the oligosaccharides with these types of
labels. Nevertheless, the data interpretation was significantly
simplified as the ionisation via pseudomolecular adduct for-
mation with Group I cations (e.g. H+, Na+, . . .) is not needed and
the [M]+ ions could be directly observed.
We previously described the synthesis of various 1-methyli-
midazolium-tagged glycosides (I-Tags) as excellent probes for
mass spectrometric analysis of enzymatic glycosylation reac-
tions even in crude sample matrices, such as milk, since these
cationic labels ionised readily and produce a dominant mass
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spectroscopy signal that can be monitored.32–34 Moreover, in a
related study we described the synthesis of cationic methylimi-
dazolium N-ethylamine (MIEA+) and demonstrated that its
use in reductive amination reactions of oligosaccharides is
feasible.35 Although these MIEA+-derivatised carbohydrates
could be ionised and identified in a proof-of-concept study,
attempts to upscale the reductive amination reaction for a more
detailed product characterisation failed. Also, a cleanup step
after the derivatisation step was required for the removal of the
sample matrix and the excess of unreacted MIEA+. To amelio-
rate these shortcomings, we hypothesised that combining an
additional aromatic moiety with a methylimidazolium ion
would not only provide the stable cationic character required
for the efficient mass spectroscopic analysis of the glycan
derivatives, but the introduction of an aromatic group facili-
tates the monitoring of the reaction progress in larger reaction
scales due to the chromophoric detection of the reactants via
UV. This proposed bifunctional imidazolium derivative (GITag,
1), which carries a permanent positive charge, was successfully
synthesised in good yield (74%) by esterification using 4-(Boc-
amino)benzoic acid and 1-hydroxylethyl-3-methylImidazolium
tetrafluoroborate (Scheme 1).
To compare the ionisation efficiency of the GITag 1 with
other commonly used tags such as 2AB, the absolute quantifi-
cation of sample concentrations is essential. Therefore,
N-acetylglucosamine (GlcNAc, 2) and lactose (Lac, 3) were both
derivatised via reductive amination with GITag and 2AB in
a preparative scale and the products obtained in good yields
(46–58%) (Scheme 2A, see ESI†). Serial dilutions of these
compounds were then subjected to ESI-ToF-LC/MS and
MALDI-ToF analysis. The limit of detection (LOD, S/N = 3)
and the limit of quantification (LOQ, S/N = 10) of the GITag-
labelled compounds 9 and 11 showed up to a 600-fold increase
in sensitivity when compared to the 2AB-labeled carbohydrates
8 and 10 for ESI-ToF-LC/MS experiments and by a factor of 2 to
6 when using MALDI-ToF-MS (Table 1). Furthermore, com-
pounds 8–11 showed comparable fluorescence intensities in
LC-FLD analysis when using the respective optimised emission
and excitation maxima (see ESI†).
After establishing the high ionisation efficiency of the
GITagged carbohydrates, we also compared the derivatisation
efficiency of the reaction of GlcNAc and lactose with GITag 1
and 2AB using NMR spectroscopy (see ESI†). To that end,
GlcNAc or Lac were reacted with NaBH3CN in the presence of
Scheme 1 Structures of 2AB and novel GITag and synthetic route for the
synthesis of the GITag.
Scheme 2 (A) Reductive amination of GlcNAc 2 or Lac 3 with 2AB or
GITag and (B), the evolution of the w (%) of compound 8, 9, 10 and
11.















2AB-GlcNAc (8) 58 189 476 731 779 3576
GITag-GlcNAc
(9)
229 880 0.7 3.5 104 559
2AB-Lactose
(10)
3.7 20 1080 2228 686 1402
GITag-Lactose
(11)
211 602 3.1 9.7 114 685
a Fluorescence intensities were measured for compounds 8 and 10 at
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a equimolar amount of 2AB or 1 in a deuterated solvent system
(DMSO-d6/AcOH-d3 7 : 3). The conversion rate over time
(Scheme 2B) was thus monitored by 1H-NMR. Firstly, a faster
reaction rate for the monosaccharide GlcNAc was observed
when compared to the disaccharide Lac, most probably due
to the reduced sterical hindrance of the former. Secondly, for
both glycans, neutral 2AB tag results in a slightly faster con-
version rate compared to the positively charged GITag. Regard-
less, in the model system all reactions reach comparable
conversions (36 to 52%) within 16 h. We can attribute this rate
differences to the cationic nature of 1, which can interfere with
reactions involving other cationic or polar species,36,37 and thus
is likely to result in slower imine formation (known to be the
rate limiting step in reductive amination reactions).38 Since the
labelling procedure uses an excess of the tag, the small differ-
ences in rate did not pose a problem for the efficient functio-
nalization of glycans with 1, in the same timescale as done for
2AB tagging.
To demonstrate the full potential of GITag 1, we pursued the
challenge of derivatising N-glycans from a human serum sam-
ple without any pretreatment of the serum or sample clean-up
steps following the derivatisation reaction. The human serum
sample, PNGase F (the biocatalyst required for the enzymatic N-
glycan release), sodium phosphate buffer (500 mM, pH 7.5),
and the GITag derivatisation solution were deposited sequen-
tially directly on a MALDI-ToF sample carrier without the need
for any sample transfer, centrifugation steps (Scheme 3A, see
ESI†). All thirty-two major mass signals could be identified as
either complex-type (25 species), high mannose-type (5 species),
or hybrid-type (2 species) N-glycans (Scheme 3B, see ESI†), and
showed a comparable glycan distribution to reported human
plasma N-glycans.39,40 It is noteworthy that only neutral
N-glycans after GITag 1 derivatisation were identified as [M]+ ions,
whereas single-negative charged monosialylated N-glycans had
one extra sodium ion attached [M+ + Na+]+ (i.e. N-glycan
A2G2S, m/z = 2331.2), and double-negative charged disialylated
N-glycans had two extra sodium ions attached [M+2 + 2Na+]+
(i.e. N-glycan A2G2S2, m/z = 2498.5). The use of the permanently
charged GITag 1 allowed for the streamlined determination of
sialoglycans without the need of tedious pretreatment of the
sample for the neutralization by permetylation or amidation
reactions.41,42
To showcase the practical utility of GITag in comparison
with commercial 2AB on the detection of human serum
N-glycans, we undertook N-glycan derivatisation with both
labels under three different sample preparation set-ups (A)
direct on target preparation, (B) in-vial sample preparation
with one centrifugation step to remove serum debris after
PNGase F treatment, and (C) preparation of samples with a
sample clean-up using a solid phase glycan extraction step
after PNGase F treatment. In all cases, we clearly showed the
better ionisation of GITagged-glycans (see Section 4.1 and
Fig. S7 in ESI†). Moreover, we also run a comparison human
serum N-glycans labelling experiment using sample prepara-
tion (C) and the same concentrations of serum and either
GITag or 2AB43 (see Section 4.2 and Fig. S8 in ESI†). We found
that the overall serum N-glycan profiles of 2AB-labelled and
GI-Tagged serum N-glycans were essentially the same,
furthermore a direct comparison of the LCMS traces for both
labels also showed comparable fluorescence intensities for
both 2AB and GITag, with a slightly higher fluorescence at
the optimized Ex/Em wavelength of 304/368 nm of the latter.
However, as previously demonstrated, when comparing
the mass signals for both labelling strategies, significant
improvements were observed when using the GITag
(B50 times higher signal intensity when compared to 2AB
labelled N-glycans). These results further demonstrate the
versatility of the new GITag labels.
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In conclusion, we have developed a novel glycan MS sequen-
cing label, GITag 1, bearing both a MS cationic handle and
UV/fluorescent-detectable motif, which can be used as an
efficient tool for glycan sequencing. The new label is easily
accessible in good yields from commercially available starting
materials without the need for lengthy purification steps and
unlike previously developed cationic labels, carbohydrate deri-
vatisation is efficient and all reactions reach comparable con-
versions (36 to 52%) within 16 h under standard labelling
conditions. More importantly, carbohydrates labelled with the
GITag showed superior sensitivity (down to the sub-fmol range)
in mass spectrometric analysis when compared to currently
used methods. The successful derivatisation of N-glycans and
analysis of untreated human serum directly on the MALDI
sample carrier demonstrates the potential of this derivatisation
agent for a broad range of applications in glycan analysis.
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